×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
💹
Economics
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Economics
Status
Showcase
▼
Showcase
Demo
Vision
|
Showcase
←
Home
/
Wiki
/
Clinical: VY7523 Phase 1/2 Alzheimer's Disease Trial
clinical
1,123 words
KG: VY7523 Phase 1/2 Alzheimer's Disease Trial
2026-03-29
kind:clinical-trial
section:clinical-trials
topic:alzheimers
status:phase-1-2
state:published
Contents
VY7523 Phase 1/2 Alzheimer's Disease Trial
Knowledge Graph
Related Hypotheses (30)
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.83
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.83
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
TREM2-mediated microglial tau clearance enhancement
Score: 0.80
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.78
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.75
LRP1-Dependent Tau Uptake Disruption
Score: 0.75
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.74
VCP-Mediated Autophagy Enhancement
Score: 0.71
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.68
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.67
Synaptic Vesicle Tau Capture Inhibition
Score: 0.64
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.64
Extracellular Vesicle Biogenesis Modulation
Score: 0.64
APOE Isoform Expression Across Glial Subtypes
Score: 0.00
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.61
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Stress Granule Phase Separation Modulators
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
Noradrenergic-Tau Propagation Blockade
Score: 0.71
Show 25 more
Related Analyses (21)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 16 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.95
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.90
s:** - Test whether HCN1 knockout specifically in EC layer I
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40
ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated
clinical · proposed · Score: 0.40
Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecu
clinical · proposed · Score: 0.40
Cholinergic System Dysfunction in DLB — Mechanisms and Thera
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Epigenetic Regulation Dysfunction in Alzheimer's and Parkins
clinical · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Gap Junction Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Lifestyle Intervention Mechanisms in Alzheimer's Disease
validation · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism
clinical · proposed · Score: 0.40
Microglial Aging and Immune Memory in Neurodegeneration — Tr
validation · proposed · Score: 0.40
Show 25 more
See Also (15)
TREM2 Agonist Therapies for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Tau Immunotherapy for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Sodium Oligomannate (GV-971) for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Siponimod for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Nanomedicine Approaches to Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Nanomedicine for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Memantine - NMDA Antagonist for Alzheimer's Disease
therapeutic · Pages share 19 hypotheses
Kamuvudine-9: NRTI for Alzheimer's Disease Neuroinflamm
therapeutic · Pages share 18 hypotheses
Ferulic Acid Carbamate Derivatives for Alzheimer's Dise
therapeutic · Pages share 18 hypotheses
Disease-Modifying Therapies for Alzheimer's Disease
therapeutics · Pages share 19 hypotheses
CAR-T Cell Therapy for Alzheimer's Disease
therapeutic · Pages share 19 hypotheses
CAR-A (Chimeric Antigen Receptor) Astrocyte Therapy for
therapeutic · Pages share 18 hypotheses
CAR-A Therapy - Chimeric Antigen Receptor Astrocytes fo
treatment · Pages share 18 hypotheses
CAR-A Therapy — Chimeric Antigen Receptor Astrocytes fo
treatment · Pages share 18 hypotheses
Bumetanide — Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Show 10 more
Knowledge Graph (1 edges)
VY7523 Phase 1/2 Alzheimer's Disease Trial
references
APOE
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)